Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy

Zhu, Bo; Yu, Liu; Yue, Qingcai

doi:10.1016/j.biopha.2017.02.112

Cited by 59 publications

(37 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vincristine is one of the most commonly used chemotherapeutic agents for blood cancer and solid tumors. 5,6 Vincristine has been known to induce microtubule destabilisation and deficits in axonal transport, and thus, has more neurotoxicity than other vinca alkaloid agents. 7,8 Nefopam has drawn interest for its antinociceptive and antihyperalgesic effects; it acts by influencing monoamines, and the noradrenergic and/or serotonergic system, resulting in the prevention and reduction of central neural sensitisation.…”

Section: Introductionmentioning

confidence: 99%

The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice

Lee

Sim

Cho

et al. 2020

JPR

View full text Add to dashboard Cite

Background: Chemotherapy-induced neuropathic pain is a disabling condition following cancer treatment. Vincristine has more neurotoxicity than other vinca alkaloid agents. This study evaluated the correlation of different doses of nefopam with antiallodynic effects in a mouse vincristine neuropathy model. Methods: A peripheral neuropathic mouse model was made by intraperitoneal injection of vincristine (0.1 mg/kg/day; 5-day-on, 2-day-off schedule over 12 days). After the development of allodynia, mice were injected intraperitoneally with 0.9% normal saline (NS group) or various doses (10, 30, 60 mg/kg) of nefopam (Nefopam group). We examined allodynia using von Frey hairs pre-administration and at 30, 60, 90, 120, 180, 240 mins, and 24 hrs after drug administration. We also measured the neurokinin-1 receptor concentrations in the spinal cord to confirm the antiallodynic effect of nefopam after drug administration. Results: The peripheral neuropathic mouse model showed prominent mechanical allodynia. Intraperitoneal nefopam produced a clear dose-dependent increase in paw withdrawal threshold compared with pre-administration values and versus the NS group. The concentration of neurokinin-1 receptor was significantly decreased in the Nefopam group (P<0.05). Conclusion: Intraperitoneally administered nefopam yielded a dose-dependent attenuation of mechanical allodynia and decreased neurokinin-1 receptor concentration, suggesting that the neurokinin-1 receptor is involved in the antiallodynic effects of nefopam in vincristine neuropathy.

show abstract

Section: Introductionmentioning

confidence: 99%

The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice

Lee

Sim

Cho

et al. 2020

JPR

View full text Add to dashboard Cite

show abstract

“…The synergistic effect of the dual drugs loaded nanoparticles was evaluated by comparing the cytotoxicity parameters of LAC-SFN/CCM-NPs, LAC-SFN-NPs, and LAC-CCM-NPs, which were determined using a MTT assay. 39,40 HepG2 cells, sorafenib-resistant cell lines (HepG2/SFN cells), and LO2 cells were seeded in 48well plates and incubated overnight at 37°C in a 5% CO 2 incubator. LAC-SFN/CCM-NPs, LAC-NPs, LAC-SFN-NPs, LAC-CCM-NPs, SFN/CCM-NPs, and free SFN/ CCM at different drug concentrations were added into each well and incubated for 72 h. Then, MTT solution (20 μL, 5 mg/mL) was added to each well and further incubated for 4 h. Thereafter, the unreacted dye solution was removed, and DMSO solution (200 μL) was added.…”

Section: In Vitro Cytotoxicity and Synergistic Effectmentioning

confidence: 99%

Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles

Bian¹,

Guo²

2020

DDDT

View full text Add to dashboard Cite

Purpose: Hepatocellular carcinoma (HCC) is a leading cancer worldwide. In the present investigation, sorafenib (SFN) and curcumin (CCM) were co-delivered using pH-sensitive lactosylated nanoparticles (LAC-NPs) for targeted HCC treatment. Methods: pH-responsive lactosylated materials were synthesized. SFN and CCM codelivered, pH-responsive lactosylated nanoparticles (LAC-SFN/CCM-NPs) were selfassembled by using the nanoprecipitation technique. The nanoparticles were characterized in terms of particle size, charge and drug release profile. The anti-cancer effects of the nanoparticles were evaluated in human hepatic carcinoma cells (HepG2) cells and HCC tumor xenograft models. Results: LAC-SFN/CCM-NPs are spherical particles with light coats on the surface. The size and zeta potential of LAC-SFN/CCM-NPs were 115.5 ± 3.6 nm and −34.6 ± 2.4, respectively. The drug release of LAC-SFN/CCM-NPs in pH 5.5 was more efficient than in pH 7.4. LAC-SFN/CCM-NPs group exhibited the smallest tumor volume (239 ± 14 mm 3 ), and the inhibition rate of LAC-SFN/CCM-NPs was 77.4%. Conclusion: In summary, LAC-SFN/CCM-NPs was proved to be a promising system for targeted HCC therapy.

show abstract

“…Among the physicochemical characteristics of NPs, zeta potential, particle size and polydispersity index (PI) are crucial in determining nano-carriers colloidal stability, cellular or tissue uptake efficiency, biodistribution and cytotoxic effects [27][28][29]. Zeta potential has values that typically range from +100 to -100 mV and indicates the effective electric charge on the NPs surface, while PI denotes their size distribution.…”

Section: Solid Lipid Npsmentioning

confidence: 99%

“…In general, NPs with zeta potential values greater than +30 mV or less than -30 mV show increased stability due to a larger electrostatic repulsion among particles [27]. Meanwhile, a particle size between 10 and 200 nm favors the extravasation, accumulation and slowly released of bioactive compounds at the specific tumor site through the enhanced EPR effect [28,29], which is determined by the permeable vasculature and poor lymphatic drainage of the solid tumors. NPs larger than 10 nm are capable of leaking out from abnormal tumor micro-vasculature but unable to penetrate the gaps of normal blood vessels [3].…”

Section: Solid Lipid Npsmentioning

confidence: 99%

Berries polyphenols: Nano-delivery systems to improve their potential in cancer therapy

Forbes‐Hernández

2020

JBR

View full text Add to dashboard Cite

Berries bioactive compounds, specially polyphenols, have been widely recognized for their chemopreventive and chemotherapeutic properties. However, most of them struggle with chemical instability, low solubility, extensive metabolism and consequently poor bioavailability, which limit their clinical use. An effective strategy to overcome such problems consists of the nano-delivery systems. In the present review, the progress made in utilization of nano-carriers for berries polyphenols administration either alone or in combination with chemotherapeutic drugs have been summarized.

show abstract

Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy

Cited by 59 publications

References 39 publications

<p>The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice</p>

<p>The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice</p>

<p>Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles</p>

Berries polyphenols: Nano-delivery systems to improve their potential in cancer therapy

Contact Info

Product

Resources

About